Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.960
-0.630 (-13.73%)
At close: Nov 20, 2024, 4:00 PM
3.880
-0.080 (-2.02%)
Pre-market: Nov 21, 2024, 5:29 AM EST
Aclaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 27.08 | 31.25 | 29.5 | 6.64 | 6.48 | 4.23 | Upgrade
|
| Other Revenue | - | - | 0.26 | 0.12 | 0.01 | - | Upgrade
|
| Revenue | 27.08 | 31.25 | 29.75 | 6.76 | 6.48 | 4.23 | Upgrade
|
| Revenue Growth (YoY) | 26.35% | 5.03% | 340.05% | 4.30% | 53.35% | -31.28% | Upgrade
|
| Cost of Revenue | 103.99 | 116.47 | 89.77 | 48.53 | 34.47 | 68.22 | Upgrade
|
| Gross Profit | -76.91 | -85.22 | -60.02 | -41.77 | -27.99 | -63.99 | Upgrade
|
| Selling, General & Admin | 25.46 | 32.41 | 25.13 | 23.62 | 20.53 | 27.83 | Upgrade
|
| Research & Development | -40.2 | - | - | - | - | - | Upgrade
|
| Operating Expenses | -14.74 | 32.41 | 25.13 | 23.62 | 20.53 | 27.83 | Upgrade
|
| Operating Income | -62.18 | -117.63 | -85.15 | -65.38 | -48.52 | -91.82 | Upgrade
|
| Interest & Investment Income | 8.04 | 8.51 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.89 | - | 2.95 | -1.14 | -0.42 | -2.48 | Upgrade
|
| EBT Excluding Unusual Items | -53.24 | -109.12 | -82.21 | -66.53 | -48.94 | -94.3 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -18.5 | Upgrade
|
| Other Unusual Items | 22.5 | 26.9 | -4.7 | -24.34 | -2.39 | -0.73 | Upgrade
|
| Pretax Income | -37.37 | -88.85 | -86.91 | -90.87 | -51.34 | -113.54 | Upgrade
|
| Income Tax Expense | -0.37 | -0.37 | - | - | -0.18 | - | Upgrade
|
| Earnings From Continuing Operations | -37 | -88.48 | -86.91 | -90.87 | -51.15 | -113.54 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 0.14 | -47.81 | Upgrade
|
| Net Income | -37 | -88.48 | -86.91 | -90.87 | -51.02 | -161.35 | Upgrade
|
| Net Income to Common | -37 | -88.48 | -86.91 | -90.87 | -51.02 | -161.35 | Upgrade
|
| Shares Outstanding (Basic) | 71 | 70 | 65 | 57 | 43 | 41 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 70 | 65 | 57 | 43 | 41 | Upgrade
|
| Shares Change (YoY) | 3.48% | 7.05% | 14.95% | 33.36% | 2.94% | 25.57% | Upgrade
|
| EPS (Basic) | -0.52 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | Upgrade
|
| EPS (Diluted) | -0.52 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | Upgrade
|
| Free Cash Flow | -18.46 | -79.63 | -68.17 | -52.44 | -39.09 | -98.06 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -1.14 | -1.05 | -0.92 | -0.92 | -2.37 | Upgrade
|
| Gross Margin | -284.04% | -272.70% | -201.74% | - | - | - | Upgrade
|
| Operating Margin | -229.61% | -376.42% | -286.21% | -967.08% | -748.52% | -2172.23% | Upgrade
|
| Profit Margin | -136.65% | -283.15% | -292.11% | -1343.96% | -787.03% | -3817.22% | Upgrade
|
| Free Cash Flow Margin | -68.17% | -254.84% | -229.13% | -775.65% | -602.99% | -2319.80% | Upgrade
|
| EBITDA | -62.2 | -117.57 | - | -65.06 | -48.2 | -90.84 | Upgrade
|
| D&A For EBITDA | -0.03 | 0.06 | - | 0.32 | 0.32 | 0.98 | Upgrade
|
| EBIT | -62.18 | -117.63 | -85.15 | -65.38 | -48.52 | -91.82 | Upgrade
|
| EBIT Margin | -229.61% | - | -286.21% | - | - | - | Upgrade
|
| Revenue as Reported | 27.08 | 31.25 | 29.75 | 6.76 | 6.48 | 4.23 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.